213 related articles for article (PubMed ID: 17024116)
1. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
Gutiérrez NC; Castellanos MV; Martín ML; Mateos MV; Hernández JM; Fernández M; Carrera D; Rosiñol L; Ribera JM; Ojanguren JM; Palomera L; Gardella S; Escoda L; Hernández-Boluda JC; Bello JL; de la Rubia J; Lahuerta JJ; San Miguel JF;
Leukemia; 2007 Jan; 21(1):143-50. PubMed ID: 17024116
[TBL] [Abstract][Full Text] [Related]
2. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
3. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
Chang H; Ning Y; Qi X; Yeung J; Xu W
Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
[TBL] [Abstract][Full Text] [Related]
5. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
[TBL] [Abstract][Full Text] [Related]
6. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.
Chang H; Qi XY; Samiee S; Yi QL; Chen C; Trudel S; Mikhael J; Reece D; Stewart AK
Bone Marrow Transplant; 2005 Nov; 36(9):793-6. PubMed ID: 16113669
[TBL] [Abstract][Full Text] [Related]
7. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
[TBL] [Abstract][Full Text] [Related]
9. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
10. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G; Hansen T; Shimoni A; Zabelina T; Pérez-Simón JA; Gutierrez NC; Bethge W; Liebisch P; Schwerdtfeger R; Bornhäuser M; Otterstetter S; Penas EM; Dierlamm J; Ayuk F; Atanackovic D; Bacher U; Bokemeyer C; Zander A; San Miguel J; Nagler A; Kröger N
Leukemia; 2008 Jun; 22(6):1250-5. PubMed ID: 18418408
[TBL] [Abstract][Full Text] [Related]
11. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
12. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.
Chang H; Sloan S; Li D; Zhuang L; Yi QL; Chen CI; Reece D; Chun K; Keith Stewart A
Br J Haematol; 2004 Apr; 125(1):64-8. PubMed ID: 15015970
[TBL] [Abstract][Full Text] [Related]
13. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
14. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
15. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
Jiang N; Qi C; Trieu Y; Reece D; Chang H
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor.
Panani AD; Ferti AD; Papaxoinis C; Raptis SA; Roussos Ch
Anticancer Res; 2004; 24(6):4141-6. PubMed ID: 15736465
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS.
Kaufmann H; Ackermann J; Odelga V; Sagaster V; Nösslinger T; Pfeilstöcker M; Keck A; Ludwig H; Gisslinger H; Drach J
Eur J Clin Invest; 2008 Jan; 38(1):53-60. PubMed ID: 18173551
[TBL] [Abstract][Full Text] [Related]
19. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
